Following the critical need for better diagnoses in the UK, RMDM has helped develop a non-invasive blood test, PanTum Detect, which can diagnose all cancers, at any given stage of growth, and is soon to launch.
The device, which has remarkably high diagnostic accuracy, is currently accessible in Germany and Holland and is launching soon in the UK.
“RMDM has helped develop a non-invasive blood test, PanTum Detect. “
RMDM’s Chief Scientific Officer, Dr Ahmed Bourghida, stated: “Following extensive research, investment and development we are now in a position to revolutionise cancer care in the UK. Early detection of cancer is absolutely vital when it comes to improving cancer outcomes and saving lives and our unique, non-invasive blood test will take away the fear factor that many people feel around biopsies, giving the NHS the confidence to run more universal screening campaigns.”
The CHHP’s Managing Director, Elizabeth Moore stated: “Myself and the team at CHHP are absolutely thrilled to be involved in the revolutionary launch of the PanTum blood test, an innovation in cancer blood testing. CHHP has been involved in the long process of trialling and testing for many months in order to validate the test which is now ready for the UK market. The PanTum test has emerged as a unique test to the UK market, with minimal invasion and can screen for cancer before it is too late. The blood test is a significant breakthrough in proactive medical management that will enable patients and doctors alike to detect much earlier change in metabolism that differentiate cancer cells from normal cells at such an early stage. We look forward to seeing how the development of this test within the UK can grow to a nationwide service.”